Lesogaberan for Gastroesophageal Reflux Disease?

The jury is still out on this alternate approach.

Proton-pump inhibitors (PPIs) revolutionized the treatment of patients with gastroesophageal reflux disease (GERD). Although PPIs are effective for erosive esophagitis, complete symptomatic resolution of heartburn and regurgitation occurs in only an estimated 40% to 60% of treated patients.

As inappropriate transient lower esophageal sphincter relaxation (TLESR) has gained recognition as the dominant abnormality in most GERD patients, investigation has begun to focus on drug therapies in this area. Pharmacologic manipulation of gamma-aminobutyric acid type B (GABA_B) receptors has been shown to inhibit various afferent and efferent pathways involved in TLESR. Baclofen, a selective GABA_B-receptor agonist used to treat spasticity disorders, has…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors